(PDF) P1.13-44 Safety, PK, and Preliminary Antitumor

P1.13-44 Safety, PK, and Preliminary Antitumor Activity of the Oral EGFR/HER2 Exon 20 Inhibitor TAK-788 in NSCLC

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.08.901

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

October 1, 2018

Authors

Publisher

Elsevier BV

Related search

P2.13-32 TAK-788 Is a Novel and Potent Tyrosine Kinase Inhibitor With Selective Activity Against EGFR/HER2

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-42 Activity of Novel HER2 Inhibitor, Poziotinib, for HER2 Exon 20 Mutations in Lung Cancer and Mechanism of Acquired Resistance

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-05 Integrin Β3 Inhibition Enhances the Antitumor Activity of Alk Inhibitor in Alkrearranged NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.13-04 Integrin Β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK Rearranged NSCLC

Journal of Thoracic Oncology

Respiratory Medicine

English

Antitumor Activity of the Selective Pan-Raf Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma

Cancer Research

Cancer Research

English

P1.15-05 the Frequency and Spectrum of EGFR Exon 20 Insertions in NSCLC: A Global Literature Review

Journal of Thoracic Oncology

Respiratory Medicine

English

SKLB-287, a Novel Oral Multikinase Inhibitor of EGFR and VEGFR2, Exhibits Potent Antitumor Activity in LoVo Colorectal Tumor Model

Cancer Research

English

Antitumor Activity of the Polo-Like Kinase Inhibitor, TAK-960, Against Preclinical Models of Colorectal Cancer

Cancer Research

English

P3.01-96 Clinical Characteristics of Non–Small Cell Lung Cancer Harboring Mutations in Exon 20 of EGFR or HER2

Journal of Thoracic Oncology

Respiratory Medicine

English